Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Genetic Alterations in Thyroid Cancer: Resistance to BRAFi and Anaplastic Transformation

Oncotarget

February 8, 2024
In a new research perspective, researchers discuss the role of genetic alterations in mediating resistance to BRAF inhibition and anaplastic transformation in thyroid cancer. continue reading »

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma

News

February 7, 2024
PRESS RELEASE: On February 5, 2024, a new research perspective was published in Oncotarget, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.” continue reading »

Drug Discovery in Academia; Dumping in the Publication Landfill?

News

February 5, 2024
PRESS RELEASE: On January 24, 2024, a new editorial was published in Oncotarget, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?” continue reading »

BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients

News

January 31, 2024
PRESS RELEASE: On January 24, 2024, a new research paper was published in Oncotarget, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.” continue reading »

Genetic Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition and Anaplastic Transformation

News

January 29, 2024
PRESS RELEASE: On January 24, 2024, a new research perspective was published in Oncotarget, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.” continue reading »